CRANDELL KEITH — SEC Form 4 filings
SEC reporting owner CIK 1219039. 20 Form 4 filings on record with FilingPulse; latest filed 2026-07-06.
Transaction summary — filings shown
Covers all 20 filings on record, filed 2024-02-09 to 2026-07-06. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 13 legs across 9 filings — 15,224,493 shares, $140,499,943 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 1 leg across 1 filing — 16,000 shares, $39,840 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 47.
- Largest priced transaction: purchase of 1,432,224 shares @ $18.00 ($25,780,032) in Metsera, Inc., filed 2025-02-03.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Metsera, Inc. (MTSR) | Director, 10% owner | 2 | 2 legs · 2,222,222 sh · $39,999,996 | — | 9 |
| Prime Medicine, Inc. (PRME) | 10% owner | 2 | 2 legs · 6,230,300 sh · $29,999,990 | — | — |
| Kardigan, Inc. (KARD) | Director, 10% owner | 2 | 1 leg · 1,250,000 sh · $20,000,000 | — | 4 |
| Seaport Therapeutics, Inc. (SPTX) | 10% owner | 1 | 1 leg · 1,100,000 sh · $19,800,000 | — | 4 |
| Lyell Immunopharma, Inc. (LYEL) | 10% owner | 2 | 1 leg · 488,090 sh · $12,499,985 | — | — |
| Sana Biotechnology, Inc. (SANA) | 10% owner | 1 | 3 legs · 1,818,181 sh · $9,999,996 | — | — |
| Neumora Therapeutics, Inc. (NMRA) | 10% owner | 1 | 1 leg · 1,915,700 sh · $4,999,977 | — | — |
| Boundless Bio, Inc. (BOLD) | 10% owner | 2 | 2 legs · 200,000 sh · $3,200,000 | 1 leg · 16,000 sh · $39,840 | 12 |
| 908 Devices Inc. (MASS) | Director | 3 | — | — | 12 |
| Rapport Therapeutics, Inc. (RAPP) | 10% owner | 1 | — | — | 3 |
+1 more issuer among the filings shown — every filing appears in the table below.
Form 4 filings — CRANDELL KEITH
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-06 | 4 | Boundless Bio, Inc. (BOLD) jointly with BYBEE CLINTON, NELSEN ROBERT, GILLIS STEVEN, Burow Kristina | Option exercise (M): 16,000 @ $1.03 · Sale (S): 16,000 @ $2.49 · Option exercise (M): 16,000 (derivative) @ $0 | EDGAR |
| 2026-06-24 | 4 | Kardigan, Inc. (KARD) jointly with ARCH Venture Partners XIII, LLC, ARCH Venture Partners XIII, L.P., ARCH Venture Fund XIII, L.P., NELSEN ROBERT, Burow Kristina, GILLIS STEVEN | Purchase (P): 1,250,000 @ $16 | EDGAR |
| 2026-06-22 | 4 | Kardigan, Inc. (KARD) jointly with ARCH Venture Partners XIII, LLC, ARCH Venture Partners XIII, L.P., ARCH Venture Fund XIII, L.P., NELSEN ROBERT, Burow Kristina, GILLIS STEVEN | Conversion (C): 13,792,035 · Conversion (C): 5,148,587 (derivative) · Conversion (C): 1,204,000 (derivative) · Conversion (C): 2,306,401 (derivative) | EDGAR |
| 2026-06-12 | 4 | 908 Devices Inc. (MASS) | Option exercise (M): 14,083 · Option exercise (M): 14,083 (derivative) @ $0 · Grant/award (A): 13,656 (derivative) @ $0 · Grant/award (A): 6,209 (derivative) @ $0 | EDGAR |
| 2026-05-04 | 4 | Seaport Therapeutics, Inc. (SPTX) jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., NELSEN ROBERT, Burow Kristina, GILLIS STEVEN | Conversion (C): 2,513,686 · Conversion (C): 2,681,265 · Purchase (P): 1,100,000 @ $18 · Conversion (C): 2,513,686 (derivative) @ $0 · Conversion (C): 2,681,265 (derivative) @ $0 | EDGAR |
| 2026-03-09 | 4 | Lyell Immunopharma, Inc. (LYEL) jointly with ARCH Venture Fund XIII, L.P., ARCH Venture Partners XIII, L.P., ARCH Venture Partners XIII, LLC, NELSEN ROBERT, Burow Kristina, GILLIS STEVEN, BERNS PAUL L, BYBEE CLINTON | Purchase (P): 488,090 @ $25.61 | EDGAR |
| 2026-02-09 | 4 | Twist Bioscience Corp (TWST) | Grant/award (A): 5,095 @ $0 | EDGAR |
| 2025-11-14 | 4 | Metsera, Inc. (MTSR) jointly with ARCH Venture Partners XII, LLC, ARCH Venture Fund XII, L.P., ARCH Venture Partners XII, L.P., ARCH Venture Fund XIII, L.P., ARCH Venture Partners XIII, L.P., ARCH Venture Partners XIII, LLC, GILLIS STEVEN, NELSEN ROBERT | Disposition to issuer (D): 18,503,128 · Disposition to issuer (D): 8,313,680 | EDGAR |
| 2025-10-29 | 4 | Neumora Therapeutics, Inc. (NMRA) jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., GILLIS STEVEN, NELSEN ROBERT, BYBEE CLINTON | Purchase (P): 1,915,700 @ $2.61 | EDGAR |
| 2025-08-01 | 4 | Prime Medicine, Inc. (PRME) jointly with ARCH Venture Partners X, LLC, ARCH Venture Partners X, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Fund X, L.P., ARCH Venture Fund X Overage, L.P., Burow Kristina, GILLIS STEVEN | Purchase (P): 3,030,300 @ $3.30 | EDGAR |
| 2025-07-29 | 4 | Lyell Immunopharma, Inc. (LYEL) jointly with ARCH Venture Partners IX, LLC, ARCH Venture Partners IX, L.P., ARCH Venture Partners IX Overage, L.P., ARCH Venture Fund IX, L.P., ARCH Venture Fund IX Overage, L.P., BYBEE CLINTON, NELSEN ROBERT | Holdings only — no transactions reported | EDGAR |
| 2025-06-13 | 4 | 908 Devices Inc. (MASS) | Option exercise (M): 11,364 · Option exercise (M): 11,364 (derivative) @ $0 · Grant/award (A): 14,083 (derivative) @ $0 · Grant/award (A): 6,516 (derivative) @ $0 | EDGAR |
| 2025-02-07 | 4 | Twist Bioscience Corp (TWST) | Grant/award (A): 4,472 @ $0 | EDGAR |
| 2025-02-03 | 4 | Metsera, Inc. (MTSR) jointly with ARCH Venture Partners XII, LLC, ARCH Venture Fund XII, L.P., ARCH Venture Partners XII, L.P., ARCH Venture Fund XIII, L.P., ARCH Venture Partners XIII, L.P., ARCH Venture Partners XIII, LLC, GILLIS STEVEN, NELSEN ROBERT | Conversion (C): 16,006,949 · Conversion (C): 7,523,682 · Purchase (P): 1,432,224 @ $18 · Purchase (P): 789,998 @ $18 · Conversion (C): 19,933,333 (derivative) · Conversion (C): 15,000,000 (derivative) · +3 more | EDGAR |
| 2024-06-14 | 4 | 908 Devices Inc. (MASS) | Option exercise (M): 7,777 · Option exercise (M): 7,777 (derivative) @ $0 · Grant/award (A): 11,364 (derivative) @ $0 · Grant/award (A): 15,996 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | Rapport Therapeutics, Inc. (RAPP) jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., NELSEN ROBERT, Burow Kristina, GILLIS STEVEN | Conversion (C): 3,728,738 @ $0 · Conversion (C): 20,000,000 (derivative) @ $0 · Conversion (C): 11,924,138 (derivative) @ $0 | EDGAR |
| 2024-04-04 | 4 | Boundless Bio, Inc. (BOLD) jointly with BYBEE CLINTON, NELSEN ROBERT, GILLIS STEVEN | Conversion (C): 589,743 · Conversion (C): 787,545 · Conversion (C): 1,048,433 · Purchase (P): 66,667 @ $16 · Purchase (P): 133,333 @ $16 · Conversion (C): 424,908 (derivative) · +6 more | EDGAR |
| 2024-02-20 | 4 | Prime Medicine, Inc. (PRME) jointly with ARCH Venture Partners X, LLC, ARCH Venture Partners X, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Fund X, L.P., ARCH Venture Fund X Overage, L.P., Burow Kristina, GILLIS STEVEN | Purchase (P): 3,200,000 @ $6.25 | EDGAR |
| 2024-02-12 | 4 | Sana Biotechnology, Inc. (SANA) jointly with BYBEE CLINTON, Burow Kristina, GILLIS STEVEN | Purchase (P): 363,637 @ $5.50 · Purchase (P): 727,272 @ $5.50 · Purchase (P): 727,272 @ $5.50 | EDGAR |
| 2024-02-09 | 4 | Twist Bioscience Corp (TWST) | Grant/award (A): 5,815 @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1219039 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →